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Abstract
Purpose Dose, fractionation, normalization and the dose profile inside the target volume vary substantially in pulmonary
stereotactic body radiotherapy (SBRT) between different institutions and SBRT technologies. Published planning studies
have shown large variations of the mean dose in planning target volume (PTV) and gross tumor volume (GTV) or internal
target volume (ITV) when dose prescription is performed to the PTV covering isodose. This planning study investigated
whether dose prescription to the mean dose of the ITV improves consistency in pulmonary SBRT dose distributions.
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Materials and methods This was a multi-institutional planning study by the German Society of Radiation Oncology
(DEGRO) working group Radiosurgery and Stereotactic Radiotherapy. CT images and structures of ITV, PTV and all
relevant organs at risk (OAR) for two patients with early stage non-small cell lung cancer (NSCLC) were distributed to
all participating institutions. Each institute created a treatment plan with the technique commonly used in the institute for
lung SBRT. The specified dose fractionation was 3× 21.5Gy normalized to the mean ITV dose. Additional dose objectives
for target volumes and OAR were provided.
Results In all, 52 plans from 25 institutions were included in this analysis: 8 robotic radiosurgery (RRS), 34 intensity-
modulated (MOD), and 10 3D-conformal (3D) radiation therapy plans. The distribution of the mean dose in the PTV did
not differ significantly between the two patients (median 56.9Gy vs 56.6Gy). There was only a small difference between
the techniques, with RRS having the lowest mean PTV dose with a median of 55.9Gy followed by MOD plans with
56.7Gy and 3D plans with 57.4Gy having the highest. For the different organs at risk no significant difference between
the techniques could be found.
Conclusions This planning study pointed out that multiparameter dose prescription including normalization on the mean
ITV dose in combination with detailed objectives for the PTV and ITV achieve consistent dose distributions for peripheral
lung tumors in combination with an ITV concept between different delivery techniques and across institutions.
Keywords Stereotactic radiation therapy · Lung cancer · Organs at risk · Planning benchmark study · Quality assurance ·
Dose prescription
Introduction
Lung cancer is responsible for the highest number of cancer
deaths in males and females worldwide. Surgical resection
is standard of care, but growing numbers of patients are
medically inoperable due to their age and comorbidities.
In patients with untreated early stage non-small cell lung
cancer (NSCLC) the median survival is 13 months and the
5-year cancer-specific survival rate is 16% [1]. In these
patients, being inoperable or refusing surgery, the standard
of care is stereotactic body radiation therapy (SBRT) [2–5].
Furthermore, SBRT is increasingly applied for patients with
lung metastases in the oligometastatic disease [6–12].
Despite the fact that the use of SBRT is rapidly increas-
ing, there is high variability in prescribed doses and normal-
ization methods between prospective trials, between institu-
tions and even between practice guidelines, which makes it
difficult to compare the truly delivered dose and the treat-
ment outcome between institutions. A recent multicenter
planning study from Giglioli et al. [13] showed that the
general equivalent uniform planning target volume (PTV)
dose varied between 105 and162Gy if only the dose per
fraction was specified without further specification on the
dose prescription and normalization method, the dose inho-
mogeneity and PTV constraints.
Historically an inhomogeneous dose was prescribed to
a certain PTV encompassing isodose line, normalization
was done on the maximum dose or a representative dose
point inside the target volume. This is in agreement with
the International Commission on Radiation Units and Mea-
surements (ICRU) reports 50 and 62 [14, 15] which rec-
ommend prescription and normalization on a representa-
tive point. ICRU 83 [16] for modulated treatment planning
recommends dose prescription to the median PTV dose in-
stead of prescribing and reporting the dose to a single point.
The new ICRU report 91 [17] recommends for stereotactic
treatments to prescribe the dose to the isodose surface that
covers an optimal percentage of the PTV. Additionally, it
is recommended that the prescription does not only spec-
ify the prescribed dose and the normalization method but
a comprehensive set of accepted values for target coverage
and organ at risk doses. A recent multi-enter planning study
from the German Society of Radiation Oncology (DEGRO)
working group for Radiosurgery and Stereotactic Radio-
therapy [18] showed that interinstitutional variation in the
mean PTV dose was reduced by specifying the dose as well
as the prescription method; the prescribed dose of 3× 15Gy
had to cover 95% of the PTV and the allowed D2% was
set to 69.2Gy. However, the variability was still >22%,
and there was a large difference between the SBRT tech-
niques. Similarly, all other dosimetric parameters charac-
terizing gross tumor volume (GTV) and PTV dose showed
large differences.
Based on the European Society for Radiotherapy and
Oncology (ESTRO) and Advisory Committee on Radia-
tion Oncology Practice (ACROP) consensus guidelines for
SBRT of peripherally located NSCLC [19], de Jong et al.
published recommendations for prescribing and recording
taking the ICRU report 91 into account [20]. They showed
that even between 8 centers having long-term clinical ex-
perience with SBRT significant differences can be seen in
the actual planned dose to the PTVs and GTVs.
There is strong retrospective data indicating that this
variation in GTV and PTV doses is of clinical relevance.
Several studies reported that local tumor control after pul-
monary SBRT was significantly associated with the biolog-
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Table 1 The different objectives for the treatment planning. Minor deviations were allowed in the order of the objectives in the table
Objective Allowed deviation
PTV coverage D95%> 70%
(= 45.2Gy, BED= 112 Gy10)
D90%> 70%
(= 45.2Gy, BED= 112 Gy10)
ITV coverage D95%> 90%
(= 58.1Gy, BED= 170 Gy10)
D90%> 90%
(= 58.1Gy, BED= 170 Gy10)
CIRTOG=V70%/V(PTV) <1.20 <1.25
D0.1ml <107%
(= 69Gy, BED= 228 Gy10)
<110%
(= 71Gy, BED= 239 Gy10)
PTV planning taget volume, D95% dose to 95% of the volume, BED biologically effective dose, ITV internal target volume, CIRTOG Radiation
Therapy Oncology Group conformity index, V70% volume recieving 70% of the prescribed dose, V(PTV) volume of the planning target volume
ically effective dose (BED) at the isocenter and the mean
GTV dose [21–23]. There is consequently a clinical need to
better standardize the planning of pulmonary SBRT and to
reduce interinstitutional variability. As basis for this study,
we postulate a multiparameter dose prescription including
dose normalization to the mean ITV dose in combination
with specification of more detailed PTV and ITV objec-




This study was conducted in the DEGRO working group
Radiosurgery and Stereotactic Radiotherapy. The same two
patients as in the work of Moustakis et al. [18] with inopera-
ble early stage NSCLC were selected for this study to allow
comparison with previous results (Fig. 1). Since the pa-
tients were anonymized and from a previous investigation,
Fig. 1 Axial and coronal CT
slices with structures of the two
patients used for this planning
study
no ethics approval was needed. Patient 1 had a peripheral
lesion in the left upper lobe and patient 2 had a peripheral
lesion in the right lower lobe. Contouring of the GTV was
performed in the lung window and an internal target vol-
ume (ITV) was generated as the encompassing of all tumor
positions based on a four dimensional (4D) computed to-
mography (CT). An ITV to planning target volume (PTV)
margin 5mm was applied resulting in PTV sizes of 23.8cm3
and 19.4cm3, respectively. Ipsi- and contralateral lung, the
chest wall, spinal cord and esophagus were delineated as
organs-at-risk (OAR) for both patients.
CT images and structures of ITV, PTV and all relevant
OARs for these two patients were sent to 27 participat-
ing institutions, all having experience in pulmonary SBRT.
Each institute was asked to create a treatment plan with the
technique commonly used in the institute for lung SBRT,




The multiparameter dose prescription included a normaliza-
tion of 3× 21.5Gy to the mean ITV dose (BED= 203 Gy10).
An additional set of dose objectives as shown in Table 1
was provided. This is based on an internal prestudy at the
University Hospital of Zürich, which showed that this cor-
responds to a prescription of 3× 15Gy to the 65% isodose
for conformal treatment plans (BED= 112 Gy10), therefore
fulfilling national and international guidelines (see supple-
mental material). No recommendations concerning dose-
calculation algorithm, calculation-grid-size or MLC-leaf-
width were given.
For OARs, the constraints from the DEGRO guidelines
[22] were used. These were as low as reasonably achievable
(ALARA) for the bilateral lungs, a dose to 0.1ml of the
spinal canal below 18Gy and the volume of the thoracic
wall receiving 30Gy or more below 30ml.
Analysis
All plans were transferred into the MIM software (MIM
software Inc., Cleveland, OH, USA) for analysis. The plans
were divided into different categories depending on the
SBRT technique used: robotic radiosurgery (RRS); modu-
lated RT (MOD) including static intensity modulated ther-
apy (IMRT) as well as intensity modulated arc therapy
(IMAT); and 3D techniques (3D) including conformal arc
(CA) as well as 3D conformal radiotherapy (3DRT). The
planning systems and dose calculation algorithms were also
evaluated. A dose–volume histogram (DVH) binning of
0.1Gy was used for the evaluation in MIM.
For dosimetric evaluation of the ITV and PTV, the mean
and median dose as well as the dose to 2% and 98% of
the PTV were recorded according to the ICRU guidelines
[14–17]. Furthermore, coverage of the ITV with the 90%
and of the PTV with the 70% isodose were evaluated and
the dose to 0.1ml of the PTV. To assess the conformity of
the plans, two different conformity indices (CI) were used:
Fig. 2 Examples of dose distributions for the different techniques used in this planning study: a robotic radiosurgery (RSS), b modulated (MOD)
and c 3D-conformal radiotherapy (3D)
 The Radiation Therapy Oncology Group (RTOG) CI
[24], which indicates the volume of healthy tissue rela-
tive to the PTV size exposed to the prescribed dose:
CIRTOG = V.45.2Gy/=VPTV
 The Paddick CI [25], which quantifies the high dose out-
side the tumor as well as the coverage of the tumor:
CIPaddick = V2PTV.45.2Gy/=.V.45.2Gy/  VPTV/
Where VPTV is the volume of the PTV, V(45.2Gy) is the
volume receiving at least 45.2Gy and VPTV (45.2Gy) is the
volume of the PTV receiving at least 45.2Gy.
To access the lower dose bath of the plans, the gradient
index (GI) was also evaluated:
GI = V.22.6Gy/=V.45.2Gy/
The lungs (mean lung dose [MLF]) and thoracic wall
(volume receiving minimally 30Gy) were evaluated as
OARs. All other OAR were not relevant for these cases.
Kruskal–Wallis test implemented in MATLAB Version
R2016a (The MathWorks Inc, Natick, MA, USA) was used
to compare results for PTV, ITV and OAR parameters be-
tween different delivery techniques and algorithms used for
dose calculation. Since the primary interest of this study
was the difference in the mean PTV dose, no correction for
multiple testing was applied for this variable. For all other
parameters, statistics were corrected for multiple testing.
P values below 0.05 were considered significant.
Results
Data collected
A total of 57 SBRT plans from 27 institutions were ana-
lyzed in this study. These were 8 robotic radiosurgery (RRS,
14%), 34 modulated plans (MOD, 60%), and 15 3D confor-
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Fig. 3 Distribution of algo-
rithms by different techniques
used, robotic radiosurgery
(RRS), modulated (MOD) and
3D-conformal radiotherapy
(3D). Separation between Monte
Carlo algorithms (MC), algo-
rithms based on the Boltzmann
transport equation (BT), col-
lapsed cone algorithms (CC),
analytical anisotropic algorithms
(AAA) and pencil beam algo-
rithms (PB). PB algorithms were
















Table 2 Minor deviations from the planning objectives by different techniques and dose calculation algorithms
Deviation RRS MOD 3D MC BT CC AAA PB Total
CI 0 3 4 2 0 3 2 0 7
D0.1ml 1 0 4 2 0 2 0 1 5
PTV coverage 0 3 0 0 2 0 1 0 3
ITV coverage 0 0 1 0 0 1 0 0 1
RRS robotic radiosurgery, MOD modulated radiotherapy, 3D 3D-conformal radiotherapy, MCMonte Carlo algorithm, BT algorithms based on the
Boltzmann transport equation, CC collapsed cone algorithms, AAA analytical anisotropic algorithms, PB pencil beam algorithms, CI conformity
index, D0.1 ml Dose to 0.1ml, PTV planning target volume, ITV internal target volume
mal (3D) plans (26%). Examples of the dose distribution for
the different treatment techniques are shown in Fig. 2. Five
different dose calculation algorithms were used; 21% of the
plans were calculated with a Monte Carlo (MC) algorithm,
28% with an algorithm using the Boltzmann transport equa-
tion (BT), 17% used a collapsed cone (CC) algorithm, 26%
the analytical anisotropy algorithm (AAA) and 7% a pencil
beam algorithm (PB). The use of different dose calculation
algorithms for the different treatment techniques is visual-
ized in Fig. 3. Since usage of the PB does not comply with
national and international guidelines [17, 19, 26, 27] these
plans were discarded in the analysis. Results including these
plans can be found in the supplemental material.
The multileaf collimator (MLC) width for the MLC
Linac-based plans varied between 2.5mm and 10mm
(17× 2.5mm, 2× 4mm, 28× 5mm, 2× 10mm). Most plans
used either 6 MV with flattening filter (FF; 37 plans) or
flattening filter-free (FFF) beam (16 plans). Only 4 plans
were created using 10 MV FFF beams. It is also worth to
notice that only one institution used an MLC with 1cm
leave width (2 plans), all others Linac-based plans used
either 2.5mm (17 plans), 4mm (2 plans) or 5mm leave
width (28). All RRS plans were created using cones of dif-
ferent sizes with the minimal size being 12.5mm (2 plans)
or 15mm (6 plans).
One MOD plan did not fulfill the constraints (too high
conformity index) and was removed from the analysis. An-
other 18 cases showed a minor deviation. These minor de-
viations are summarized in Table 2.
Due to removal of plans calculated with PB and the one
not fulfilling the constraints, 52 plans from 25 institutions
were included in the final analysis.
Characterization of the dose to the target volumes
Different dosimetric parameters for the two patients and
different treatment techniques are summarized in Table 3.
Due to the normalization, the mean ITV dose was identi-
cal in all cases and the median dose in the ITV varied only
marginally (64.1–65.7Gy for patient 1 and 64.2–65.4Gy for
patient 2). The median coverage of the ITV with the 90%
isodose was above 99.1% (95.2–100%) for patient 1 and
98.5% (94.2–100%) for patient 2. No significant difference
K
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Table 3 Results for the two patients and the different techniques. The plan which did not fulfill the constraint and the plans calculated with the
pencil beam algorithm were excluded
Patient 1 Patient 2
RRS MOD 3D RRS MOD 3D
ITV Dmedian Median 65.0Gy 64.7Gy 65.0Gy 64.7Gy 64.6Gy 64.7Gy
Mean 65.1Gy 64.6Gy 64.9Gy 64.7Gy 64.7Gy 64.7Gy
Std 0.6Gy 0.2Gy 0.3Gy 0.3Gy 0.3Gy 0.2Gy
ITV V90% Median 98.0% 99.6% 98.8 97.6% 98.9% 97.9%
Mean 97.7% 99.0% 98.5% 97.5% 98.7% 97.5%
Std 1.9% 1.1% 0.9% 1.7% 1.2% 2.3%
PTV Dmean Median 56.2Gy 56.9Gy 57.8Gy 55.6Gy 56.6Gy 57.2Gy
Mean 56.2Gy 56.9Gy 57.7Gy 55.7Gy 56.6Gy 57.0Gy
Std 0.6Gy 0.8Gy 0.7Gy 0.3Gy 0.5Gy 0.6Gy
PTV Dmedian Median 55.7Gy 57.0Gy 58.8Gy 54.8Gy 56.5Gy 57.5Gy
Mean 55.5Gy 57.2Gy 58.4Gy 54.9Gy 56.7Gy 57.1Gy
Std 1.2Gy 1.2Gy 1.0Gy 0.4Gy 1.1Gy 1.0Gy
PTV V70% Median 97.8% 96.6% 96.2% 96.2% 95.9% 95.9%
Mean 97.6% 97.0% 96.4% 96.4% 95.7% 96.9%
Std 2.1% 1.7% 0.7% 0.8% 2.4% 0.8%
D0.1ml Median 68.6Gy 67.7Gy 67.8Gy 68.9Gy 67.5Gy 69.4Gy
Mean 68.7Gy 67.6Gy 67.8Gy 69.1Gy 67.8Gy 69.3Gy
Std 0.7Gy 1.1Gy 0.4Gy 0.6Gy 1.0Gy 0.5Gy
PTV D2% Median 67.9Gy 67.1Gy 67.3Gy 68.3Gy 67.4Gy 68.8Gy
Mean 67.8Gy 66.9Gy 67.2Gy 68.6Gy 67.3Gy 68.6Gy
Std 0.6Gy 0.8Gy 0.3Gy 0.7Gy 0.8Gy 0.4Gy
PTV D98% Median 45.0Gy 44.2Gy 43.8Gy 44.2Gy 44.0Gy 43.2Gy
Mean 44.6Gy 43.9Gy 43.6Gy 44.2Gy 43.2Gy 43.4Gy
Std 1.6Gy 3.1Gy 0.4Gy 0.5Gy 3.2Gy 0.9Gy
PTV CIRTOG Median 1.13 1.14 1.20 1.11 1.12 1.20
Mean 1.13 1.13 1.18 1.10 1.12 1.20
Std 0.04 0.07 0.04 0.05 0.05 0.04
PTV CIPaddick Median 0.85 0.84 0.78 0.84 0.83 0.77
Mean 0.85 0.83 0.78 0.85 0.82 0.77
Std 0.02 0.05 0.02 0.03 0.05 0.03
PTV GI Median 3.76 4.21 4.13 3.93 4.22 4.46
Mean 4.03 4.14 4.51 4.03 4.34 4.77
Std 0.77 0.31 1.07 0.53 0.49 1.14
Ipsilateral lung
Dmean
Median 5.8Gy 5.4Gy 5.8Gy 4.2Gy 3.4Gy 3.5Gy
Mean 6Gy 5.4Gy 5.6Gy 4.1Gy 3.5Gy 3.5Gy
Std 0.4Gy 0.5Gy 0.3Gy 0.3Gy 0.5Gy 0.3Gy
Contralateral
lung Dmean
Median 1.0Gy 0.8Gy 0.7Gy 0.7Gy 0.6Gy 0.6Gy
Mean 1.0Gy 0.8Gy 0.8Gy 0.7Gy 0.6Gy 0.6Gy
Std 0.2Gy 0.1Gy 0.1Gy 0.2Gy 0.2Gy 0.1Gy
Thoracic wall
V30Gy
Median 7.2ml 7.3ml 7.6ml – – –
Mean 7.3ml 7.3ml 7.6ml – – –
Std 1.5ml 0.7ml 0. ml – – –
RRS robotic radiosurgery, MOD modulated radiotherapy, 3D 3D-conformal radiotherapy, ITV internal target volume, Vx% volume recieving x%
of the prescribed dose, PTV planning target volume, Dx% Dose to x% of the volume, CI conformity index, GI gradient index
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Fig. 4 a, b The mean planning target volume (PTV) dose; c, d the coverage of the PTV with the 70% (= 45.2Gy) isodose V(70%) for different
treatment techniques and dose calculation algorithms (Monte Carlo algorithm [MC], algorithms based on the Boltzmann transport equation [BT],
collapsed cone algorithms [CC] and analytical anisotropic algorithms [AAA]), respectively. e The gradient index (GI) and f the mean dose to
the ipsilateral lung for different treatment techniques (robotic radiosurgery [RRS], modulated radiotherapy [MOD] and 3D-conformal radiother-
apy [3D]). The plan which did not fulfill the constraint and the plans calculated with the pencil beam algorithm were excluded
K
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between SBRT techniques or dose calculation algorithms
was observed.
The distributions of the mean PTV dose did not differ
significantly between the two patients (median 56.9Gy vs
56.6Gy). There was a significant but small difference be-
tween the techniques (p< 0.01), with RRS having the lowest
mean PTV dose with median 55.9Gy (range 55.4–56.9Gy)
followed by MOD plans with 56.6Gy (55.4–58.5Gy) and
3D plans characterized by the highest dose with 57.4Gy
(56.0–58.1Gy) as shown in Fig. 4a. Difference between
dose calculation algorithms was also significant (p= 0.01)
with highest PTV doses observed for the CC algorithm and
lowest for the MC algorithm (Fig. 4b). The median dose to
the PTV showed a very similar pattern.
The coverage of the PTV with the 70% isodose
(= 45.2Gy) showed no significant variation between the
techniques and algorithms as shown in Fig. 4c,d. However,
there was some residual interinstitutional variation (median
96.1%, range 90–100%), with four plans being below 95%
coverage (3 MOD plans and 1 3D plan).
Doses to 0.1ml, 2% and 98% of the PTV were com-
parable between the different techniques and algorithms.
Regarding D98% there were 3 outliers to lower dose val-
ues, 1 for patient 1 (32.6Gy [MOD, AAA]) and 2 for pa-
tient 2 (32.6Gy [MOD, AAA] and 39.4Gy [MOD, BT]).
The lowest values for each patient originated from the same
institution.
There was no significant interinstitutional or intertech-
nology variability regarding the conformity indices (Ta-
ble 3) or gradient index. However, the GI showed consider-
able interinstitutional variation (median 4.2, range 3.4–6.7).
An example of the difference in the 22.6Gy isodose line
used for the GI can be found in the supplemental material.
Characterization of the dose to the OAR
No significant difference between the techniques were ob-
served for the OARs. The median of the mean dose to
the ipsilateral lung was 5.8Gy (RRS), 5.4Gy (MOD) and
5.8Gy (3D) for patient 1 and 4.2Gy (RRS), 3.4Gy (MOD)
and 3.5Gy (3D) for patient 2 (Fig. 4f). However, while
there was no significant difference between the algorithms
for patient 1, there was one for patient 2 (p= 0.03), MC
algorithms calculated the highest dose, while AAA algo-
rithms suggested the lowest dose in the ipsilateral lung.
The contralateral lung only received very low doses, me-
dian 0.8Gy (range 0.6–1.2Gy) for patient 1 and median
0.6Gy (range 0.5–1.2Gy) for patient 2. For patient 1 the
volume of the thoracic wall receiving 30Gy was 7.3ml
with a range of 5.6–9.2ml. For patient 2 the PTV was dis-
tant to the thoracic wall such that maximum doses were
below 30Gy.
Discussion
SBRT is used widely for primary lung tumors such as
NSCLC as well as for pulmonary oligometastatic disease
[2–4, 9, 28]. Recommendations for these treatments exist
from different organizations [19, 22, 26, 29]. However, even
following these, significant differences between studies, in-
stitutions and SBRT techniques for doses to target volumes
as well as OAR have been published [13, 18, 30, 31].
In the current study, dose prescription to the mean ITV
dose combined with additional ITV- and PTV-based plan-
ning objectives achieved highly consistent dose distribu-
tions within the target volume. Mean and median dose to
the PTV varied by less than 3% of the prescribed dose,
which is of the order of magnitude as treatment planning
for a static phantom [26, 32]. This high consistency was
achieved despite the large number of participating institu-
tions (n= 27), the use of heterogeneous planning techniques
and planning for all currently available SBRT delivery plat-
forms. We are therefore convinced that the proposed pul-
monary SBRT planning and dose prescription methodology
is generalizable.
We believe that in particular the use of several DVH-
based planning objectives for the ITV and PTV contributed
to homogenize dose distribution between centers. Unfortu-
nately, the ICRU Report 91 for stereotactic treatments [17]
still recommends only to prescribe to one single DVH point
of the PTV and does not give any additional objectives for
GTV, CTV or ITV as already discussed in [33]. However, it
recommends reporting multiple dose parameters for GTV,
CTV, ITV and PTV to make treatment outcome more com-
parable.
The recent study evaluating the difference in dose to
GTV and PTV of multiple centers [20] concluded that
a multiparametric prescription is needed. The study sug-
gests as minimum requirement a BED10 of 150Gy as mean
ITV dose. However, our study showed that even a higher
dose to the ITV is possible.
The single SBRT plan with an inacceptable deviation
in CI and 4 plans out of 7 with minor deviations for the
CI were observed for one specific planning system. This
demonstrates the general problem that volume calculation
and also the display of contours and dose may differ signif-
icantly between planning systems depending on how calcu-
lation voxels are then interpolated. In all cases the planning
institution assumed to fulfill the planning objectives when
plan evaluation was performed in the respective planning
system. This clearly indicates the need that vendors agree
on one common way to interpret partial volume effects be-
tween voxels and DICOM structures. The other three mi-
nor deviations for the conformity index showed no particu-
lar pattern and originated from different planning systems.
Four out of five minor deviations of the dose to 0.1ml of
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the PTV were planned with a 3D static field technique. Us-
ing 3D conformal forward planning, it is obviously more
difficult to simultaneously control all parameters. Similarly,
no pattern was observed for the deviations in ITV and PTV
coverage.
All OAR constraints OAR were fulfilled by all institu-
tions and by all SBRT plans for both patients. All insti-
tutions followed the ALARA principle and achieved very
similar results of OAR sparing, irrespective of the SBRT
planning and delivery technique.
The significant difference in the ipsilateral mean lung
dose as a function of algorithm is interesting. Nevertheless,
they might have to be allocated to the fact that for RRS
only MC was used for the dose calculation while for MOD
treatments, BT and AAA dominate and for the 3D treatment
plans, CC dominates. Even though the deviations we see are
small, according to ICRU 91 and other recommendations
[17, 26, 29] a type B or MC algorithm, which takes into
account the lateral electron scattering in inhomogeneous
media, should be used for SBRT, in particular in the lung. In
addition, the abovementioned recommendations suggest the
use of a calculation grid of 2mm or smaller, but for 13 plans
a calculation grid of 2.5mm, for 5 plans a calculation grid
of 3mm and for 3 plans a calculation grid of as large as
4mm was used. In particular the use of a calculation grid
larger than 3mm should be avoided; however, nowadays
with sufficient computing power, grid sizes of 2mm should
be feasible in daily routine practice.
Possibly, part of the deviations which were accepted
by the planner, could be omitted if regular knowledge-
exchange and training was performed on national and in-
ternational level. This is in line with a survey on the In-
fluence of Institutional Experience and Technological Ad-
vances on Outcome of Stereotactic Body Radiation Therapy
for Oligometastatic Lung Disease [34] which showed a re-
lation between the local control and the experience of the
center, as well as with a recent review on dosimetric mul-
ticenter planning comparison studies for SBRT [35] and
two other multicentric planning studies for spine SBRT and
prostate SBRT [36, 37].
One of the limitations of this study is that only two pa-
tients were evaluated which are not representative for all
patients. We added to the supplemental material a further
study containing 40 patients, where we evaluated the opti-
mal constraints for the planning study in order to have min-
imal variation in different dosimetric parameters between
the different patients. However, these were only planned by
one single institution. Therefore, conclusions drawn from
this study should be evaluated on more patients in a multi-
center setting.
A further limitation is the fact that motion management
of different institutions was not evaluated. Nevertheless,
a recent detailed 4D dose analysis has indicated negligible
difference and variability of GTV mean and near minimum
dose between ITV-based and mid-ventilation-based PTV
optimization and GTV-based robust optimization provided
that normalization is done to the GTV mean dose [38].
Using different motion management strategies might have
resulted in smaller doses to the OAR as for this study the
target contours were delineated based on an ITV concept.
Furthermore, this study relies on the correct dose calcula-
tion of the plans, independent from the treatment algorithm
used and no dosimetric evaluation of the applicability of
the plans was performed. Additionally, the dose to the ITV
and not to the GTV was reported in our study, as this would
require a full 4D dose calculation taking the range of mo-
tion into account; however, it has been shown that there is
very close association between mean ITV and GTV dose
despite large interpatient variations in GTV volume and
motion range [39–41]. In the cases where no ITV was de-
fined due to a different motion management, prescribing to
the mean dose to the GTV might thus be equivalent to pre-
scribing to the mean ITV dose as used in this study while
prescribing to the mean PTV dose might not be the optimal
strategy.
We evaluated the study according to the recently pub-
lished Radiotherapy Treatment plannINg study Guide-
lines (RATING) [42] and achieved a score of 166 out of
186 points (89%), even though the study was conducted
before these guidelines had been published.
Conclusions
Analyzing 52 plans from 25 institutions, this planning study
demonstrated that dose prescription to the mean internal
target volume (ITV) dose in combination with detailed
dose–volume histogram (DVH)-based planning objectives
for planning target volume (PTV) and ITV achieves highly
consistent dose distributions irrespective of the planning
institution, and the stereotactic body radiotherapy (SBRT)
planning and delivery technologies. We therefore recom-
mend to evaluate the proposed planning approach.
Supplementary Information The online version of this article (https://
doi.org/10.1007/s00066-021-01799-w) contains supplementary mate-
rial, which is available to authorized users.
Funding Open Access funding provided by Universität Zürich.
Conflict of interest L. Wilke, C. Moustakis, O. Blanck, D. Albers,
C. Albrecht, Y. Avcu, R. Boucenna, K. Buchauer, T. Etzelstorfer,
C. Henkenberens, D. Jeller, K. Jurianz, C. Kornhuber, M. Kretschmer,
S. Lotze, K. Meier, P. Pemler, A. Riegler, A. Röser, D. Schmidhalter,
K.H. Spruijt, G. Surber, V. Vallet, R. Wiehle, J. Willner, P. Winkler,
A. Wittig, M. Guckenberger and S. Tanadini-Lang declare that they
have no competing interests.
Open Access This article is licensed under a Creative Commons At-
tribution 4.0 International License, which permits use, sharing, adapta-
K
Strahlenther Onkol
tion, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article’s Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included
in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view
a copy of this licence, visit http://creativecommons.org/licenses/by/4.
0/.
References
1. Raz DJ, Zell JA, Ou SI et al (2007) Natural history of stage I
non-small cell lung cancer: implications for early detection. Chest
132(1):193–199
2. Rocco G, Morabito A, Leone A et al (2016) Management of non-
small cell lung cancer in the era of personalized medicine. Int J
Biochem Cell Biol 78:173–179
3. Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative ra-
diotherapy versus lobectomy for operable stage I non-small-cell
lung cancer: a pooled analysis of two randomised trials. Lancet On-
col 16(6):630–637
4. Guckenberger M, Allgäuer M, Appold S et al (2013) Safety and
efficacy of stereotactic body radiotherapy for stage I non–small-
cell lung cancer in routine clinical practice: a patterns-of-care and
outcome analysis. J Thorac Oncol 8(8):1050–1058
5. Maquilan G, Timmerman R (2016) Stereotactic body radiation ther-
apy for early-stage lung cancer. Cancer J 22(4):274–279. https://
doi.org/10.1097/ppo.0000000000000204
6. Collen C, Christian N, Schallier D et al (2014) Phase II study of
stereotactic body radiotherapy to primary tumor and metastatic lo-
cations in oligometastatic nonsmall-cell lung cancer patients. Ann
Oncol 25(10):1954–1959
7. Guckenberger M, Klement RJ, Allgäuer M et al (2016) Local tumor
control probability modeling of primary and secondary lung tumors
in stereotactic body radiotherapy. Radiother Oncol 118(3):485–491
8. Iyengar P, Kavanagh BD, Wardak Z et al (2014) Phase II trial of
stereotactic body radiation therapy combined with erlotinib for pa-
tients with limited but progressive metastatic non–small-cell lung
cancer. J Clin Oncol 32(34):3824–3830
9. Rieber J, Streblow J, Uhlmann L et al (2016) Stereotactic body ra-
diotherapy (SBRT) for medically inoperable lung metastases—A
pooled analysis of the German working group “stereotactic radio-
therapy”. J Lung Cancer 97:51–58
10. Rusthoven KE, Kavanagh BD, Burri SH et al (2009) Multi-institu-
tional phase I/II trial of stereotactic body radiation therapy for lung
metastases. J Clin Oncol 27(10):1579–1584
11. Tanadini-Lang S, Rieber J, Filippi AR et al (2017) Nomogram
based overall survival prediction in stereotactic body radiotherapy
for oligo-metastatic lung disease. Radiother Oncol 123(2):182–188
12. Klement RJ, Allgäuer M, Andratschke N et al (2016) Bayesian cure
rate modeling of local tumor control: evaluation in stereotactic body
radiation therapy for pulmonary metastases. Int J Radiat Oncol Biol
Phys 94(4):841–849
13. Giglioli FR, Strigari L, Ragona R et al (2016) Lung stereotactic
ablative body radiotherapy: a large scale multi-institutional plan-
ning comparison for interpreting results of multi-institutional stud-
ies. Phys Med 32(4):600–606
14. Landberg T, Chavaudra J, Dobbs J et al (2016) Report 50. J Int
Comm Radiat Units Meas. https://doi.org/10.1093/jicru/os26.1.
Report50
15. Landberg T, Chavaudra J, Dobbs J et al (2016) Report 62. J Int
Comm Radiat Units Meas. https://doi.org/10.1093/jicru/os32.1.
Report62
16. Units ICoR, Measurements (2010) ICRU report 83 prescribing,
recording, and reporting photon-beam intensity-modulated radia-
tion therapy (IMRT). J ICRU 10(1):1–3
17. Seuntjens S, Lartigau E, Cora S et al (2014) ICRU report 91. Pre-
scribing, recording, and reporting of stereotactic treatments with
small photon beams. J ICRU 14(2):101–109
18. Moustakis C, Blanck O, Tazehmahalleh FE et al (2017) Planning
benchmark study for SBRT of early stage NSCLC. Strahlenther
Onkol 193(10):780–790
19. Guckenberger M, Andratschke N, Dieckmann K et al (2017)
ESTRO ACROP consensus guideline on implementation and prac-
tice of stereotactic body radiotherapy for peripherally located early
stage non-small cell lung cancer. Radiother Oncol 124(1):11–17
20. de Jong EEC, Guckenberger M, Andratschke N et al (2020) Vari-
ation in current prescription practice of stereotactic body radio-
therapy for peripherally located early stage non-small cell lung
cancer: Recommendations for prescribing and recording according
to the ACROP guideline and ICRU report 91. Radiother Oncol
142:217–223. https://doi.org/10.1016/j.radonc.2019.11.001
21. Baumann R, Chan MK, Pyschny F et al (2018) Clinical results of
mean GTV dose optimized robotic-guided stereotactic body radia-
tion therapy for lung tumors. Front Oncol 8:171
22. Guckenberger M, Andratschke N, Alheit H et al (2014) Definition
of stereotactic body radiotherapy. Strahlenther Onkol 190(1):26–33
23. Klement RJ, Sonke J-J, Allgäuer M et al (2020) Correlating dose
variables with local tumor control in stereotactic body radio-
therapy for early stage non-small cell lung cancer: A modelling
study on 1500 individual treatments. Int J Radiat Oncol Biol Phys
107(3):579–586. https://doi.org/10.1016/j.ijrobp.2020.03.005
24. Feuvret L, Noël G, Mazeron J-J et al (2006) Conformity index: a re-
view. Int J Radiat Oncol Biol Phys 64(2):333–342
25. Paddick I (2000) A simple scoring ratio to index the conformity of
radiosurgical treatment plans. J Neurosurg 93(Suppl 3):219–222
26. Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body
radiation therapy: the report of AAPM Task Group 101. Med Phys
37(8):4078–4101
27. Guckenberger M, Baus WW, Blanck O et al (2020) Definition and
quality requirements for stereotactic radiotherapy: consensus state-
ment from the DEGRO/DGMP Working Group Stereotactic Ra-
diotherapy and Radiosurgery. Strahlenther Onkol 196(5):417–420.
https://doi.org/10.1007/s00066-020-01603-1
28. Guckenberger M (2015) Oligoprogression. Strahlenther Onkol
191(5):453–455
29. SABR UK Consortium (2019) Stereotactic Ablative Body Radia-
tion therapy (SABR): A resource. The Royal College of Radiolo-
gists,
30. Ong CL, Verbakel WF, Cuijpers JP et al (2010) Stereotactic ra-
diotherapy for peripheral lung tumors: a comparison of volumetric
modulated arc therapy with 3 other delivery techniques. Radiother
Oncol 97(3):437–442
31. Weyh A, Konski A, Nalichowski A et al (2013) Lung SBRT: dosi-
metric and delivery comparison of RapidArc, TomoTherapy, and
IMRT. J Appl Clin Med Phys 14(4):3–13
32. Seppala J, Suilamo S, Kulmala J et al (2012) A dosimetric phan-
tom study of dose accuracy and build-up effects using IMRT and
RapidArc in stereotactic irradiation of lung tumours. Radiat Oncol
7(1):79
33. Wilke L, Andratschke N, Blanck O et al (2019) ICRU report 91 on
prescribing, recording, and reporting of stereotactic treatments with
small photon beams. Strahlenther Onkol 195(3):193–198
34. Rieber J, Abbassi-Senger N, Adebahr S et al (2017) Influence of
institutional experience and technological advances on outcome of
K
Strahlenther Onkol
stereotactic body radiation therapy for oligometastatic lung disease.
Int J Radiat Oncol Biol Phys 98(3):511–520
35. Giglioli FR, Garibaldi C, Blanck O et al (2020) Dosimetric multi-
center planning comparison studies for stereotactic body radiation
therapy: methodology and future perspectives. Int J Radiat Oncol
Biol Phys 106(2):403–412. https://doi.org/10.1016/j.ijrobp.2019.
10.041
36. Esposito M, Masi L, Zani M et al (2019) SBRT planning for spinal
metastasis: indications from a large multicentric study. Strahlenther
Onkol 195(3):226–235. https://doi.org/10.1007/s00066-018-1383-
2
37. Villaggi E, Hernandez V, Fusella M et al (2019) Plan quality
improvement by DVH sharing and planner’s experience: Results
of a SBRT multicentric planning study on prostate. Phys Med
62:73–82. https://doi.org/10.1016/j.ejmp.2019.05.003
38. Leung RWK, Chan MKH, Chiang CL et al (2020) On the pitfalls
of PTV in lung SBRT using type-B dose engine: an analysis of
PTV and worst case scenario concepts for treatment plan optimiza-
tion. Radiat Oncol 15(1):130. https://doi.org/10.1186/s13014-020-
01573-9
39. Ehrbar S, Jöhl A, Tartas A et al (2017) ITV, mid-ventilation, gating
or couch tracking—A comparison of respiratory motion-manage-
ment techniques based on 4D dose calculations. Radiother Oncol
124(1):80–88. https://doi.org/10.1016/j.radonc.2017.05.016
40. Ehrbar S, Perrin R, Peroni M et al (2016) Respiratory motion-
management in stereotactic body radiation therapy for lung can-
cer—A dosimetric comparison in an anthropomorphic lung phan-
tom (LuCa). Radiother Oncol 121(2):328–334. https://doi.org/10.
1016/j.radonc.2016.10.011
41. Guckenberger M, Wilbert J, Krieger T et al (2007) Four-dimen-
sional treatment planning for stereotactic body radiotherapy. Int J
Radiat Oncol Biol Phys 69(1):276–285. https://doi.org/10.1016/j.
ijrobp.2007.04.074
42. Hansen CR, Crijns W, Hussein M et al (2020) Radiotherapy Treat-
ment plannINg study Guidelines (RATING): a framework for
setting up and reporting on scientific treatment planning studies.
Radiother Oncol 153:67–78. https://doi.org/10.1016/j.radonc.2020.
09.033
K
